TYRA-430

Phase 1Small molecule

TTyra Biosciences, Inc

TYRA-430 is one of 5 small molecule programs targeting Metastatic Hepatocellular Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Hepatocellular CarcinomaRecruiting

Metastatic Hepatocellular CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Metastatic Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Lenvima

Eisai

Phase 2

1 3

Tyrosine Kinase Inhibitor

Pfizer

Phase 2

1 4

Visugromab

CCatalYm GmbH

Phase 2

1 5

TYRA-430

TTyra Biosciences, Inc

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Metastatic Hepatocellular Carcinoma

NCT06915753

Clinical

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Recruiting·TTyra Biosciences, Inc·Phase 1·NCT06915753·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TYRA-430. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TYRA-430 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TYRA-430. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tyra Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTyra Biosciences, Inc

TYRA-430

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News